SGP logo

SPYGLASS PHARMA INC

SGPNASDAQ
🏆 #2575 by market capUS Equity
$218.00▼ $12.86 (−5.90%)
Simulated price
🔔
Track SGP
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$869M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
36
Weak
No chart data available for SGP.

Trading Snapshot

Day Range
$214.59 – $219.20
52-Week Range
$17.06 – $32.44
Volume
$3.27B
Avg Volume
$3.30B
Shares Outstanding
33.4M
Next Earnings
Dec 4, 2026

Fundamentals Snapshot

Annual Revenue
$86M
Last Q Revenue
$20M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-3.37
Dividend Yield
—

Why Investors Own SGP

  • ✓High-growth profile — revenue up -7.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 26% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SGP logo

SPYGLASS PHARMA INC

SGP
Financial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$86M▼ −6.3% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
26.1%▲ +3.8% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$15M▼ −6.3% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10M▼ −6.3% YoY
StockOtter · stockotter.space

About SPYGLASS PHARMA INC

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
36/100

Analyst Price Target

ⓘ
Average Target
$274.82
▲ +26.1% Upside
High Target$297.03
Low Target$258.13
Based on 29 analysts

Latest News & Updates

🚀
CNBC·2h ago

SPYGLASS PHARMA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift SGP price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

SPYGLASS PHARMA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.